Literature DB >> 19037522

Polymyxins: a review of the current status including recent developments.

Andrea L Kwa1, Vincent H Tam, Matthew E Falagas.   

Abstract

INTRODUCTION: Polymyxins have become the drug of choice for treatment of multidrug-resistant gram-negative bacilli infections in Singapore, simply because these pathogens are only susceptible to either aminoglycosides and polymyxins, or polymyxins only. Furthermore, there is no new antibiotic in the pipeline that targets these difficult-to-treat infections.
MATERIALS AND METHODS: All published literatures (up to end of February 2008) regarding polymyxins are included for review.
RESULTS: This review serves to give a summary of polymyxins from the current available literature, highlighting relevant clinical studies and information that help to guide informed prescription of polymyxins, should the need arise.
CONCLUSIONS: However, there are substantial information gaps that needed to be filled urgently, to preserve the clinical utility of this very last line of antibiotic.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19037522

Source DB:  PubMed          Journal:  Ann Acad Med Singapore        ISSN: 0304-4602            Impact factor:   2.473


  20 in total

1.  Surface with antimicrobial activity obtained through silane coating with covalently bound polymyxin B.

Authors:  M Mohorcič; I Jerman; M Zorko; L Butinar; B Orel; R Jerala; J Friedrich
Journal:  J Mater Sci Mater Med       Date:  2010-07-28       Impact factor: 3.896

Review 2.  Polymyxin: Alternative Mechanisms of Action and Resistance.

Authors:  Michael J Trimble; Patrik Mlynárčik; Milan Kolář; Robert E W Hancock
Journal:  Cold Spring Harb Perspect Med       Date:  2016-10-03       Impact factor: 6.915

3.  In Vitro Activity of Polymyxin B in Combination with Various Antibiotics against Extensively Drug-Resistant Enterobacter cloacae with Decreased Susceptibility to Polymyxin B.

Authors:  Yiying Cai; Tze-Peng Lim; Jocelyn Teo; Suranthran Sasikala; Winnie Lee; Yanjun Hong; Eric Chun Yong Chan; Thean Yen Tan; Thuan-Tong Tan; Tse Hsien Koh; Li Yang Hsu; Andrea L Kwa
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

4.  Invitro Activities of Polymyxins and Rifampicin against Carbapenem Resistant Acinetobacter baumannii at a Tertiary Care Hospital from South India.

Authors:  Dheepa Muthusamy; S Sudhishnaa; Appalaraju Boppe
Journal:  J Clin Diagn Res       Date:  2016-09-01

5.  Colistin and polymyxin B for treatment of nosocomial infections in intensive care unit patients: pharmacoeconomic analysis.

Authors:  Júlia Coelho França Quintanilha; Natalia da Costa Duarte; Gustavo Rafaini Lloret; Marília Berlofa Visacri; Karen Prado Herzer Mattos; Desanka Dragosavac; Antonio Luis Eiras Falcão; Patricia Moriel
Journal:  Int J Clin Pharm       Date:  2018-12-15

6.  Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design.

Authors:  Kamilia Abdelraouf; Kirk H Braggs; Taijun Yin; Luan D Truong; Ming Hu; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2012-06-11       Impact factor: 5.191

7.  Yersinia pestis AcrAB-TolC in antibiotic resistance and virulence.

Authors:  Ida M Lister; Connor Raftery; Joan Mecsas; Stuart B Levy
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

8.  Pharmacokinetics and renal disposition of polymyxin B in an animal model.

Authors:  Kamilia Abdelraouf; Jie He; Kimberly R Ledesma; Ming Hu; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

9.  Novel coordination of lipopolysaccharide modifications in Vibrio cholerae promotes CAMP resistance.

Authors:  Carmen M Herrera; Jeremy C Henderson; Alexander A Crofts; M Stephen Trent
Journal:  Mol Microbiol       Date:  2017-10-06       Impact factor: 3.501

10.  Megalin contributes to kidney accumulation and nephrotoxicity of colistin.

Authors:  Takahiro Suzuki; Hiroaki Yamaguchi; Jiro Ogura; Masaki Kobayashi; Takehiro Yamada; Ken Iseki
Journal:  Antimicrob Agents Chemother       Date:  2013-10-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.